Bayer Aktiengesellschaft (BAYRY) Projected to Post Earnings on Wednesday

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) is expected to release its results before the market opens on Wednesday, March 4th. Analysts expect Bayer Aktiengesellschaft to post earnings of $0.18 per share and revenue of $13.0754 billion for the quarter.

Bayer Aktiengesellschaft Trading Down 1.4%

BAYRY stock opened at $12.36 on Wednesday. The firm has a fifty day moving average price of $12.26 and a 200 day moving average price of $9.72. Bayer Aktiengesellschaft has a fifty-two week low of $5.30 and a fifty-two week high of $14.85. The firm has a market cap of $48.57 billion, a PE ratio of -137.32, a price-to-earnings-growth ratio of 4.96 and a beta of 0.68. The company has a debt-to-equity ratio of 1.10, a quick ratio of 0.71 and a current ratio of 1.14.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Barclays upgraded shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Tuesday, January 6th. Zacks Research raised Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 20th. Morgan Stanley upgraded Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research report on Wednesday, December 3rd. JPMorgan Chase & Co. upgraded Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a report on Monday, December 8th. Finally, DZ Bank lowered Bayer Aktiengesellschaft from a “strong-buy” rating to a “strong sell” rating in a report on Wednesday, February 18th. Three analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy”.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.